Is the therapeutic effect of fotantinib ideal and patient feedback

Fostamatinib (also known as fostamatinib, English name: Fostamatinib) is an oral spleen tyrosine kinase (Syk) inhibitor. It is currently mainly suitable for the treatment of autoimmune diseases such as chronic immune thrombocytopenia (ITP). The drug reduces the phagocytosis of antibody-coated platelets by macrophages by inhibiting the Syk pathway, thereby increasing platelet levels. Its mechanism of action is novel and provides a new treatment option for ITP patients whose previous treatments are ineffective or who cannot tolerate first-line drugs (such as glucocorticoids and immunoglobulins).

Judging from the current clinical trial data, the overall therapeutic effect of fostatinib is positive. In a pivotal Phase III clinical study, approximately 43% of ITP patients were on treatment After treatment, the platelet level increased to ≥50×10⁹/L and was able to maintain a relatively stable state. In addition, some patients can significantly reduce bleeding symptoms, such as subcutaneous bleeding and gum bleeding, after using fostatinib, and their quality of life has also improved. For patients who are long-term dependent on hormones, the emergence of fostatinib is expected to replace some traditional treatments and reduce hormone-related side effects.

In the real feedback from patients, some people gave positive comments on the efficacy of fostatinib, saying that it has a "smooth onset of effect" and "obvious control of bleeding symptoms." Especially in cases where other treatments are ineffective, the intervention of fostatinib improves the condition and delays the progression of the disease. However, a small number of patients report that the drug has a slow onset of effect and requires continuous use for several weeks to see significant improvement. Therefore, doctors generally recommend continuous use for 8 to 12 weeks to evaluate the efficacy.

Regarding tolerability, the adverse reactions of fostatinib are generally controllable. Common side effects include diarrhea, hypertension, elevated liver enzymes, etc., which are usually mild to moderate and can be alleviated by adjusting the dose or symptomatic treatment. Some patients may experience mild fatigue or gastrointestinal discomfort when starting the medication, but most symptoms gradually reduce within a few weeks. Overall, fostatinib shows good clinical prospects and patient acceptance in the treatment of immune-related diseases such as chronic ITP.

Reference materials:https://www.drugs.com/